CRWD CrowdStrike | $205.90 -1.4% | 9/11/2026 | | Reiterated Rating | $250.00 | Outperform | 00.00% | View details for Wedbush rating of CrowdStrike (NASDAQ:CRWD) on 9/11/2026 |
DDOG Datadog | $220.43 -0.6% | 9/11/2026 | | Initiated Coverage | $260.00 ➝ $275.00 | Outperform | 00.00% | View details for Wedbush rating of Datadog (NASDAQ:DDOG) on 9/11/2026 |
ESTC Elastic | $83.61 +0.2% | 9/11/2026 | | Initiated Coverage | $125.00 | Outperform | 00.00% | View details for Wedbush rating of Elastic (NYSE:ESTC) on 9/11/2026 |
PANW Palo Alto Networks | $328.03 -3.1% | 9/11/2026 | | Initiated Coverage | $400.00 | Outperform | 00.00% | View details for Wedbush rating of Palo Alto Networks (NASDAQ:PANW) on 9/11/2026 |
RBRK Rubrik | $86.16 -3.1% | 9/11/2026 | | Initiated Coverage | $90.00 ➝ $120.00 | Outperform | 00.00% | View details for Wedbush rating of Rubrik (NYSE:RBRK) on 9/11/2026 |
S SentinelOne | $19.76 -0.3% | 9/11/2026 | | Initiated Coverage | $25.00 | Outperform | 00.00% | View details for Wedbush rating of SentinelOne (NYSE:S) on 9/11/2026 |
VRNS Varonis Systems | $44.73 -1.7% | 9/11/2026 | | Reiterated Rating | $46.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Varonis Systems (NASDAQ:VRNS) on 9/11/2026 |
ZS Zscaler | $163.87 +0.2% | 9/11/2026 | | Initiated Coverage | $215.00 | Outperform | 00.00% | View details for Wedbush rating of Zscaler (NASDAQ:ZS) on 9/11/2026 |
QLYS Qualys | $152.06 -5.9% | 9/10/2026 | | Downgrade | $175.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Qualys (NASDAQ:QLYS) on 9/10/2026 |
TLS Telos | $4.02 -14.1% | 9/10/2026 | | Downgrade | $5.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Telos (NASDAQ:TLS) on 9/10/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
DT Dynatrace | $51.18 -0.5% | 9/10/2026 | | Downgrade | $54.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Dynatrace (NYSE:DT) on 9/10/2026 |
CHKP Check Point Software Technologies | $131.87 +1.0% | 9/10/2026 | | Downgrade | $135.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Check Point Software Technologies (NASDAQ:CHKP) on 9/10/2026 |
TENB Tenable | $30.30 -5.4% | 9/10/2026 | | Downgrade | $29.00 | Outperform ➝ Underperform | 00.00% | View details for Wedbush rating of Tenable (NASDAQ:TENB) on 9/10/2026 |
PYXS Pyxis Oncology | $3.26 -0.5% | 9/10/2026 | | Boost Price Target | $6.00 ➝ $8.00 | Outperform | 00.00% | View details for Wedbush rating of Pyxis Oncology (NASDAQ:PYXS) on 9/10/2026 |
IMUX Immunic | $11.34 -4.2% | 9/10/2026 | | Reiterated Rating | $45.00 | Outperform | 00.00% | View details for Wedbush rating of Immunic (NASDAQ:IMUX) on 9/10/2026 |
IRD Opus Genetics | $6.14 +1.1% | 9/10/2026 | | Boost Price Target | $10.00 ➝ $13.00 | Outperform | 00.00% | View details for Wedbush rating of Opus Genetics (NASDAQ:IRD) on 9/10/2026 |
IRON Disc Medicine | $70.52 -4.9% | 9/10/2026 | | Reiterated Rating | $100.00 | Outperform | 00.00% | View details for Wedbush rating of Disc Medicine (NASDAQ:IRON) on 9/10/2026 |
TYRA Tyra Biosciences | $22.07 -6.3% | 9/10/2026 | | Reiterated Rating | $53.00 | Outperform | 00.00% | View details for Wedbush rating of Tyra Biosciences (NASDAQ:TYRA) on 9/10/2026 |
PHVS Pharvaris | $38.45 +2.5% | 9/9/2026 | | Set Price Target | $50.00 | Outperform | 00.00% | View details for Wedbush rating of Pharvaris (NASDAQ:PHVS) on 9/9/2026 |
BBOT BridgeBio Oncology Therapeutics | $4.97 -10.0% | 9/9/2026 | | Reiterated Rating | $25.00 | Outperform | 00.00% | View details for Wedbush rating of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) on 9/9/2026 |
BEAM Beam Therapeutics | $24.16 -0.8% | 9/9/2026 | | Reiterated Rating | $65.00 | Outperform | 00.00% | View details for Wedbush rating of Beam Therapeutics (NASDAQ:BEAM) on 9/9/2026 |
GLUE Monte Rosa Therapeutics | $14.15 -1.2% | 9/9/2026 | | Reiterated Rating | $27.00 | Outperform | 00.00% | View details for Wedbush rating of Monte Rosa Therapeutics (NASDAQ:GLUE) on 9/9/2026 |
NTLA Intellia Therapeutics | $11.80 -1.1% | 9/9/2026 | | Boost Price Target | $12.00 ➝ $13.00 | Neutral | 00.00% | View details for Wedbush rating of Intellia Therapeutics (NASDAQ:NTLA) on 9/9/2026 |
SYRE Spyre Therapeutics | $90.91 +2.5% | 9/9/2026 | | Reiterated Rating | $123.00 | Outperform | 00.00% | View details for Wedbush rating of Spyre Therapeutics (NASDAQ:SYRE) on 9/9/2026 |
PHVS Pharvaris | $38.45 +2.5% | 9/8/2026 | | Reiterated Rating | $42.00 | Outperform | 00.00% | View details for Wedbush rating of Pharvaris (NASDAQ:PHVS) on 9/8/2026 |
UBER Uber Technologies | $71.59 -1.3% | 9/8/2026 | | Reiterated Rating | $91.00 | Outperform | 00.00% | View details for Wedbush rating of Uber Technologies (NYSE:UBER) on 9/8/2026 |
ARGX argenex | $988.83 +0.5% | 9/3/2026 | | Reiterated Rating | $1,150.00 | Outperform | 00.00% | View details for Wedbush rating of argenex (NASDAQ:ARGX) on 9/3/2026 |
NTAP NetApp | $198.14 +7.9% | 9/3/2026 | | Boost Price Target | $150.00 ➝ $170.00 | Neutral | 00.00% | View details for Wedbush rating of NetApp (NASDAQ:NTAP) on 9/3/2026 |
RARE Ultragenyx Pharmaceutical | $14.33 -0.5% | 9/3/2026 | | Lower Price Target | $30.00 ➝ $23.00 | Neutral | 00.00% | View details for Wedbush rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/3/2026 |
TCRX TScan Therapeutics | $0.31 -1.2% | 9/2/2026 | | Downgrade | $1.00 | Buy ➝ Neutral | 00.00% | View details for Wedbush rating of TScan Therapeutics (NASDAQ:TCRX) on 9/2/2026 |
IRON Disc Medicine | $70.52 -4.9% | 9/2/2026 | | Boost Price Target | $88.00 ➝ $100.00 | Outperform | 00.00% | View details for Wedbush rating of Disc Medicine (NASDAQ:IRON) on 9/2/2026 |
ASND Ascendis Pharma A/S | $264.33 +1.2% | 9/1/2026 | | Reiterated Rating | $327.00 | Outperform | 00.00% | View details for Wedbush rating of Ascendis Pharma A/S (NASDAQ:ASND) on 9/1/2026 |
META Meta Platforms | $650.24 +0.9% | 9/1/2026 | | Reiterated Rating | $595.00 | Neutral | 00.00% | View details for Wedbush rating of Meta Platforms (NASDAQ:META) on 9/1/2026 |
VRSN VeriSign | $291.60 +1.0% | 9/1/2026 | | Boost Price Target | $324.00 ➝ $341.00 | Outperform | 00.00% | View details for Wedbush rating of VeriSign (NASDAQ:VRSN) on 9/1/2026 |
CBIO Crescent Biopharma | $19.41 -0.3% | 8/27/2026 | | Reiterated Rating | $27.00 | Outperform | 00.00% | View details for Wedbush rating of Crescent Biopharma (NASDAQ:CBIO) on 8/27/2026 |
NVDA NVIDIA | $219.05 +0.3% | 8/27/2026 | | Boost Price Target | $330.00 ➝ $345.00 | Outperform | 00.00% | View details for Wedbush rating of NVIDIA (NASDAQ:NVDA) on 8/27/2026 |
P Everpure | $97.43 +3.5% | 8/27/2026 | | Boost Price Target | $127.00 ➝ $130.00 | Outperform | 00.00% | View details for Wedbush rating of Everpure (NYSE:P) on 8/27/2026 |
RVMD Revolution Medicines | $203.91 +0.3% | 8/27/2026 | | Boost Price Target | $201.00 ➝ $225.00 | Outperform | 00.00% | View details for Wedbush rating of Revolution Medicines (NASDAQ:RVMD) on 8/27/2026 |
SYRE Spyre Therapeutics | $90.91 +2.5% | 8/26/2026 | | Lower Price Target | $130.00 ➝ $123.00 | Outperform | 00.00% | View details for Wedbush rating of Spyre Therapeutics (NASDAQ:SYRE) on 8/26/2026 |
BBY Best Buy | $91.19 +3.5% | 8/24/2026 | | Reiterated Rating | | Buy | 00.00% | View details for Wedbush rating of Best Buy (NYSE:BBY) on 8/24/2026 |
Your book attached (Ad) Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link.
He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. Download the Safe Trade Options Formula book for free before access closes |
SRRK Scholar Rock | $55.59 -0.1% | 8/21/2026 | | Reiterated Rating | $64.00 | Outperform | 00.00% | View details for Wedbush rating of Scholar Rock (NASDAQ:SRRK) on 8/21/2026 |
P Everpure | $97.43 +3.5% | 8/21/2026 | | Boost Price Target | $105.00 ➝ $127.00 | Outperform | 00.00% | View details for Wedbush rating of Everpure (NYSE:P) on 8/21/2026 |
DASH DoorDash | $201.55 +0.3% | 8/20/2026 | | Boost Price Target | $205.00 ➝ $220.00 | Neutral | 00.00% | View details for Wedbush rating of DoorDash (NASDAQ:DASH) on 8/20/2026 |
WIX Wix.com | $76.59 +1.4% | 8/20/2026 | | Boost Price Target | $55.00 ➝ $80.00 | Neutral | 00.00% | View details for Wedbush rating of Wix.com (NASDAQ:WIX) on 8/20/2026 |
DUOL Duolingo | $144.16 -0.7% | 8/20/2026 | | Boost Price Target | $139.00 ➝ $150.00 | Neutral | 00.00% | View details for Wedbush rating of Duolingo (NASDAQ:DUOL) on 8/20/2026 |
EXPE Expedia Group | $281.57 +1.7% | 8/20/2026 | | Boost Price Target | $334.00 ➝ $417.00 | Outperform | 00.00% | View details for Wedbush rating of Expedia Group (NASDAQ:EXPE) on 8/20/2026 |
EBAY eBay | $107.33 +2.2% | 8/20/2026 | | Boost Price Target | $135.00 ➝ $137.00 | Outperform | 00.00% | View details for Wedbush rating of eBay (NASDAQ:EBAY) on 8/20/2026 |
CRTO Criteo | $17.52 +0.9% | 8/20/2026 | | Lower Price Target | $30.00 ➝ $25.00 | Outperform | 00.00% | View details for Wedbush rating of Criteo (NASDAQ:CRTO) on 8/20/2026 |
TLX Telix Pharmaceuticals | $11.29 -5.2% | 8/20/2026 | | Reiterated Rating | $22.00 | Outperform | 00.00% | View details for Wedbush rating of Telix Pharmaceuticals (NASDAQ:TLX) on 8/20/2026 |
AKTS Aktis Oncology | $23.74 -0.8% | 8/19/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Wedbush rating of Aktis Oncology (NASDAQ:AKTS) on 8/19/2026 |
CLYM Climb Bio | $14.26 -4.6% | 8/19/2026 | | Reiterated Rating | $20.00 | Outperform | 00.00% | View details for Wedbush rating of Climb Bio (NASDAQ:CLYM) on 8/19/2026 |
ARDX Ardelyx | $3.64 +0.4% | 8/18/2026 | | Reiterated Rating | $9.00 | Outperform | 00.00% | View details for Wedbush rating of Ardelyx (NASDAQ:ARDX) on 8/18/2026 |
ARGX argenex | $988.83 +0.5% | 8/18/2026 | | Boost Price Target | $1,050.00 ➝ $1,150.00 | Outperform | 00.00% | View details for Wedbush rating of argenex (NASDAQ:ARGX) on 8/18/2026 |
RNAC Cartesian Therapeutics | $8.32 -1.3% | 8/18/2026 | | Reiterated Rating | $38.00 | Outperform | 00.00% | View details for Wedbush rating of Cartesian Therapeutics (NASDAQ:RNAC) on 8/18/2026 |
WLDN Willdan Group | $82.10 +0.2% | 8/18/2026 | | Reiterated Rating | $130.00 | Outperform | 00.00% | View details for Wedbush rating of Willdan Group (NASDAQ:WLDN) on 8/18/2026 |
IMUX Immunic | $11.34 -4.2% | 8/17/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Wedbush rating of Immunic (NASDAQ:IMUX) on 8/17/2026 |
VERA Vera Therapeutics | $34.73 +3.4% | 8/17/2026 | | Reiterated Rating | $34.00 | Neutral | 00.00% | View details for Wedbush rating of Vera Therapeutics (NASDAQ:VERA) on 8/17/2026 |
GLOB Globant | $37.58 +2.4% | 8/14/2026 | | Downgrade | $54.00 ➝ $37.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Globant (NYSE:GLOB) on 8/14/2026 |
EIKN Eikon Therapeutics | $8.97 -2.6% | 8/14/2026 | | Lower Price Target | $5.00 ➝ $4.00 | Underperform | 00.00% | View details for Wedbush rating of Eikon Therapeutics (NASDAQ:EIKN) on 8/14/2026 |
FATE Fate Therapeutics | $2.34 +0.2% | 8/14/2026 | | Reiterated Rating | $7.00 | Outperform | 00.00% | View details for Wedbush rating of Fate Therapeutics (NASDAQ:FATE) on 8/14/2026 |
SNDK Sandisk | $1,631.33 -3.6% | 8/14/2026 | | Reiterated Rating | $2,000.00 | Outperform | 00.00% | View details for Wedbush rating of Sandisk (NASDAQ:SNDK) on 8/14/2026 |
ZBIO Zenas BioPharma | $31.46 +1.1% | 8/14/2026 | | Reiterated Rating | $45.00 | Outperform | 00.00% | View details for Wedbush rating of Zenas BioPharma (NASDAQ:ZBIO) on 8/14/2026 |
ANRO Alto Neuroscience | $32.08 +1.3% | 8/13/2026 | | Boost Price Target | $24.00 ➝ $26.00 | Neutral | 00.00% | View details for Wedbush rating of Alto Neuroscience (NYSE:ANRO) on 8/13/2026 |
BTGO BTGO | $7.61 +2.6% | 8/13/2026 | | Lower Price Target | $15.00 ➝ $8.00 | Outperform | 00.00% | View details for Wedbush rating of BTGO (NYSE:BTGO) on 8/13/2026 |
CBRS Cerebras Systems | $190.10 -0.6% | 8/13/2026 | | Boost Price Target | $280.00 ➝ $290.00 | Outperform | 00.00% | View details for Wedbush rating of Cerebras Systems (NASDAQ:CBRS) on 8/13/2026 |
CGEM Cullinan Therapeutics | $20.58 -2.0% | 8/13/2026 | | Boost Price Target | $39.00 ➝ $42.00 | Outperform | 00.00% | View details for Wedbush rating of Cullinan Therapeutics (NASDAQ:CGEM) on 8/13/2026 |
KURA Kura Oncology | $11.50 -0.6% | 8/13/2026 | | Boost Price Target | $36.00 ➝ $38.00 | Outperform | 00.00% | View details for Wedbush rating of Kura Oncology (NASDAQ:KURA) on 8/13/2026 |
STAA STAAR Surgical | $22.43 -4.2% | 8/13/2026 | | Lower Price Target | $40.00 ➝ $37.00 | Outperform | 00.00% | View details for Wedbush rating of STAAR Surgical (NASDAQ:STAA) on 8/13/2026 |
STRO Sutro Biopharma | $16.79 -5.9% | 8/13/2026 | | Reiterated Rating | $60.00 | Outperform | 00.00% | View details for Wedbush rating of Sutro Biopharma (NASDAQ:STRO) on 8/13/2026 |
TRAX First Tracks Biotherapeutics | $36.16 -4.8% | 8/13/2026 | | Boost Price Target | $60.00 ➝ $70.00 | Outperform | 00.00% | View details for Wedbush rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 8/13/2026 |
NCMI National CineMedia | $2.41 -2.2% | 8/12/2026 | | Set Price Target | $6.00 ➝ $5.00 | Outperform | 00.00% | View details for Wedbush rating of National CineMedia (NASDAQ:NCMI) on 8/12/2026 |
IMNM Immunome | $24.98 +0.0% | 8/12/2026 | | Boost Price Target | $31.00 ➝ $35.00 | Outperform | 00.00% | View details for Wedbush rating of Immunome (NASDAQ:IMNM) on 8/12/2026 |
COAG Hemab Therapeutics | $39.81 -0.2% | 8/12/2026 | | Boost Price Target | $55.00 ➝ $64.00 | Outperform | 00.00% | View details for Wedbush rating of Hemab Therapeutics (NASDAQ:COAG) on 8/12/2026 |
BCAX Bicara Therapeutics | $23.01 -0.4% | 8/12/2026 | | Boost Price Target | $30.00 ➝ $33.00 | Outperform | 00.00% | View details for Wedbush rating of Bicara Therapeutics (NASDAQ:BCAX) on 8/12/2026 |
ZURA Zura Bio | $5.25 -2.5% | 8/12/2026 | | Boost Price Target | $15.00 ➝ $22.00 | Outperform | 00.00% | View details for Wedbush rating of Zura Bio (NASDAQ:ZURA) on 8/12/2026 |
FENC Adherex Technologies | $10.94 -3.2% | 8/12/2026 | | Boost Price Target | $13.00 ➝ $16.00 | Outperform | 00.00% | View details for Wedbush rating of Adherex Technologies (NASDAQ:FENC) on 8/12/2026 |
SMCI Super Micro Computer | $39.85 +6.6% | 8/12/2026 | | Boost Price Target | $34.00 ➝ $40.00 | Neutral | 00.00% | View details for Wedbush rating of Super Micro Computer (NASDAQ:SMCI) on 8/12/2026 |
VOR Vor Biopharma | $22.69 +1.6% | 8/12/2026 | | Boost Price Target | $18.00 ➝ $27.00 | Neutral | 00.00% | View details for Wedbush rating of Vor Biopharma (NASDAQ:VOR) on 8/12/2026 |
ORKA Oruka Therapeutics | $92.61 +1.1% | 8/11/2026 | | Reiterated Rating | $165.00 | Outperform | 00.00% | View details for Wedbush rating of Oruka Therapeutics (NASDAQ:ORKA) on 8/11/2026 |
RCKT Rocket Pharmaceuticals | $3.31 -4.8% | 8/11/2026 | | Lower Price Target | $16.00 ➝ $15.00 | Outperform | 00.00% | View details for Wedbush rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 8/11/2026 |
VERA Vera Therapeutics | $34.73 +3.4% | 8/11/2026 | | Lower Price Target | $43.00 ➝ $34.00 | Neutral | 00.00% | View details for Wedbush rating of Vera Therapeutics (NASDAQ:VERA) on 8/11/2026 |
JBIO Jade Biosciences | $17.68 -7.6% | 8/10/2026 | | Boost Price Target | $45.00 ➝ $47.00 | Outperform | 00.00% | View details for Wedbush rating of Jade Biosciences (NASDAQ:JBIO) on 8/10/2026 |
PTGX Protagonist Therapeutics | $147.98 +1.9% | 8/10/2026 | | Boost Price Target | $118.00 ➝ $173.00 | Outperform | 00.00% | View details for Wedbush rating of Protagonist Therapeutics (NASDAQ:PTGX) on 8/10/2026 |
SION Sionna Therapeutics | $7.67 +0.6% | 8/10/2026 | | Downgrade | $5.00 | Outperform ➝ Neutral | 00.00% | View details for Wedbush rating of Sionna Therapeutics (NASDAQ:SION) on 8/10/2026 |
SRRK Scholar Rock | $55.59 -0.1% | 8/10/2026 | | Reiterated Rating | $58.00 | Outperform | 00.00% | View details for Wedbush rating of Scholar Rock (NASDAQ:SRRK) on 8/10/2026 |
TTWO Take-Two Interactive Software | $216.99 +0.0% | 8/10/2026 | | Reiterated Rating | $300.00 | Outperform | 00.00% | View details for Wedbush rating of Take-Two Interactive Software (NASDAQ:TTWO) on 8/10/2026 |
REPL Replimune Group | $12.92 -2.4% | 8/7/2026 | | Upgrade | $12.00 | Neutral ➝ Outperform | 00.00% | View details for Wedbush rating of Replimune Group (NASDAQ:REPL) on 8/7/2026 |
ABNB Airbnb | $169.86 +1.3% | 8/7/2026 | | Upgrade | $152.00 ➝ $200.00 | Neutral ➝ Outperform | 00.00% | View details for Wedbush rating of Airbnb (NASDAQ:ABNB) on 8/7/2026 |
FRHC Freedom | $166.46 +2.3% | 8/6/2026 | | Set Price Target | $180.00 | | 00.00% | View details for Wedbush rating of Freedom (NASDAQ:FRHC) on 8/6/2026 |
FLUT Flutter Entertainment | $100.91 +2.3% | 8/6/2026 | | Lower Price Target | $138.00 ➝ $126.00 | Outperform | 00.00% | View details for Wedbush rating of Flutter Entertainment (NYSE:FLUT) on 8/6/2026 |
The end may be near for these iconic stocks (Ad) Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
APP AppLovin | $324.79 +3.3% | 8/6/2026 | | Lower Price Target | $640.00 ➝ $610.00 | Outperform | 00.00% | View details for Wedbush rating of AppLovin (NASDAQ:APP) on 8/6/2026 |
TASK TaskUs | $8.16 +6.8% | 8/6/2026 | | Lower Price Target | $12.00 ➝ $9.00 | Outperform | 00.00% | View details for Wedbush rating of TaskUs (NASDAQ:TASK) on 8/6/2026 |
TVTX Travere Therapeutics | $66.71 -1.2% | 8/6/2026 | | Boost Price Target | $61.00 ➝ $75.00 | Outperform | 00.00% | View details for Wedbush rating of Travere Therapeutics (NASDAQ:TVTX) on 8/6/2026 |
RVMD Revolution Medicines | $203.91 +0.3% | 8/6/2026 | | Boost Price Target | $192.10 ➝ $201.00 | Outperform | 00.00% | View details for Wedbush rating of Revolution Medicines (NASDAQ:RVMD) on 8/6/2026 |
RCUS Arcus Biosciences | $24.55 -6.1% | 8/6/2026 | | Boost Price Target | $41.00 ➝ $43.00 | Outperform | 00.00% | View details for Wedbush rating of Arcus Biosciences (NYSE:RCUS) on 8/6/2026 |
BCRX BioCryst Pharmaceuticals | $8.16 -1.6% | 8/6/2026 | | Lower Price Target | $21.00 ➝ $20.00 | Outperform | 00.00% | View details for Wedbush rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) on 8/6/2026 |
EBAY eBay | $107.33 +2.2% | 8/6/2026 | | Reiterated Rating | $135.00 | Outperform | 00.00% | View details for Wedbush rating of eBay (NASDAQ:EBAY) on 8/6/2026 |
EXPE Expedia Group | $281.57 +1.7% | 8/6/2026 | | Reiterated Rating | $334.00 | Outperform | 00.00% | View details for Wedbush rating of Expedia Group (NASDAQ:EXPE) on 8/6/2026 |
SHOP Shopify | $129.65 +2.4% | 8/6/2026 | | Boost Price Target | $155.00 ➝ $176.00 | Outperform | 00.00% | View details for Wedbush rating of Shopify (NASDAQ:SHOP) on 8/6/2026 |
SOLV Solventum | $87.55 -0.1% | 8/6/2026 | | Boost Price Target | $94.00 ➝ $101.00 | Outperform | 00.00% | View details for Wedbush rating of Solventum (NYSE:SOLV) on 8/6/2026 |